Pro DC
箱(W) 說明(H)
nib).pdf x
↑
X
gs
638 (3/14)
125%
...
Table 1. Effect of lazertinib on reversing the MDR mediated by ABCB1 or
ABCG2 in drug selected resistant cancer cells
IC 50 ± SD (µM) (fold reversal)
Compounds
KB (parental)
KBv200 (ABCB1)
Vincristine
0.0059 +0.0323
(1.00)
0.2263 ± 0.0323 (1.00)
+0.0625 µM Lazertinib
0.0053 ± 0.0003
(1.12)
0.0041 ± 0.0002 (1.43)
0.0782 +0.0182** (2.89)
0.0195 ±0.0105**
+0.125 µM Lazertinib
(11.60)
0.0090 0.0011** (25.21)
+0.25 µM Lazertinib
0.0050 +0.0007 (1.54)
0.0042 ± 0.0002 (1,47)
0.0100 ± 0.0038** (22.60)
+10 µM Verapamil
Doxorubicin
0.0218 ± 0.0038 (1.00)
1.2091±0.4592 (1.00)
+0.0625 µM Lazertinib
0.0216 ± 0.0093 (1.01)
0.4347±0.0807**
(2.76)
+0.125 uM Lazertinib
SD
alo
and
*p
exp
tor
res
an
apy
ure
wh
ing
E Confe
100%
M
C
從表1年
對受質車
ABCG2
然而·L=
劑的IC5C
藥物敏感